Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $2.9 million.

  • Fulcrum Therapeutics' Accounts Payables fell 2932.44% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 2932.44%. This contributed to the annual value of $1.2 million for FY2024, which is 5778.02% down from last year.
  • Fulcrum Therapeutics' Accounts Payables amounted to $2.9 million in Q3 2025, which was down 2932.44% from $1.8 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Accounts Payables' 5-year high stood at $6.0 million during Q1 2022, with a 5-year trough of $1.2 million in Q4 2024.
  • In the last 5 years, Fulcrum Therapeutics' Accounts Payables had a median value of $3.7 million in 2021 and averaged $3.6 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Accounts Payables skyrocketed by 3101.17% in 2023, and later crashed by 6092.82% in 2025.
  • Fulcrum Therapeutics' Accounts Payables (Quarter) stood at $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then fell by 24.22% to $2.8 million in 2023, then plummeted by 57.78% to $1.2 million in 2024, then surged by 145.36% to $2.9 million in 2025.
  • Its Accounts Payables was $2.9 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.5 million in Q1 2025.